Dopaminergic modulation of adenylate cyclase stimulation by vasoactive intestinal peptide in anterior pituitary.
The activation of adenylate cyclase [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] by vasoactive intestinal peptide (VIP) was used as a model to investigate the molecular mechanisms triggered by the occupancy of dopamine recognition sites in rat anterior pituitary. Dopamine failed to change the basal enzyme activity, but it inhibited the stimulation of adenylate cyclase elicited by VIP. Apomorphine, 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, and 2-bromo-alpha-ergocryptine mimicked the effect of dopamine, whereas (-)-sulpiride and and classical neuroleptics antagonized it. Dopamine failed to modulate the activation of pituitary adenylate cyclase by prostaglandin E1, which does not increase prolactin secretion. From these results we infer that stimulation of D-2 (dopamine) receptors may affect pituitary secretion by inhibiting the activation of anterior pituitary adenylate cyclase by VIP or other secretagogues.
D000262:Adenylyl Cyclases / Q000378:metabolism*; D000527:Alprostadil; D000818:Animals; D002069:Butaclamol / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology*; D004789:Enzyme Activation; D005768:Gastrointestinal Hormones / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D010646:Phentolamine / Q000494:pharmacology; D010903:Pituitary Gland, Anterior / Q000201:enzymology*; D011458:Prostaglandins E / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013469:Sulpiride / Q000494:pharmacology; D014268:Trifluoperazine / Q000494:pharmacology; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology*
D005768:Gastrointestinal Hormones; D011458:Prostaglandins E; D014268:Trifluoperazine; D014660:Vasoactive Intestinal Peptide; D013469:Sulpiride; D002069:Butaclamol; D000262:Adenylyl Cyclases; D000527:Alprostadil; D004298:Dopamine; D010646:Phentolamine